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Effects of switching between anti-TNF therapies on HAQ response in
patients who do not respond to their first anti-TNF drug
K. L. Hyrich, M. Lunt, W. G. Dixon, K. D. Watson and D. P. M. Symmons on behalf of the BSR
Biologics Register
Objectives. Small studies have shown an improvement in disease activity in patients with RA who have switched between anti-TNF therapies
for reasons of inefficacy. However, it is not clear whether switching improves longer term outcomes, such as disability. This analysis
compares changes in HAQ scores 1yr following lack of response to a first anti-TNF based on subsequent treatment during that year.
Methods. Analysis was limited to RA patients with inefficacy to a first anti-TNF based on (i) clinician opinion and/or (ii) disease activity score
in 28 joints and had an HAQ measured at time of non-response and 12 months later. Patients were classified into three groups based on
treatment during the next 12 months: (i) continued anti-TNF despite non-response; (ii) stopped anti-TNF with no further biologics; and (iii)
switched to a second anti-TNF. Mean improvement in HAQ was compared among the groups using multivariable linear regression models.
Results. As of July 2006, 868 patients met the inclusion for this analysis. Four hundred and seventy-nine patients stopped anti-TNF of whom
331 switched to a second anti-TNF. Three hundred and eighty-nine continued treatment. Patients who continued and those who switched had
improvements in HAQ over the 12 months, unlike patients who discontinued all biologic therapy. The best improvement was seen in those
who switched [adjusted mean improvement in HAQ 0.15 (95% CI 0.26, 0.05)].
Conclusion. There is a significant improvement in HAQ in patients who switch to a second anti-TNF, providing an effective next choice of
therapy for some patients who fail to respond to their first anti-TNF.
KEY WORDS: Rheumatoid arthritis, Anti-tumour necrosis factor therapy, Disease-modifying anti-rheumatic drugs, Disability, Treatment response,
Switching.
Introduction
Anti-TNF therapies represent a significant advance in the
management of severe RA. Randomized controlled trials esti-
mated upwards of 50–70% of patients achieve at least an ACR20
response [1–4]. More recently, observational data of large patient
registries have shown similar results with  70% of patients
achieving at least a European League Against Rheumatism
(EULAR) moderate response [5]. However, what is inevitable in
these data is that approximately one-third of the patients do not
achieve these minimum responses. Recent observational data has
also shown that  30% of patients will discontinue their first
course of anti-TNF therapy within the first year [6–9].
After failing anti-TNF therapy, the further management
options for these patients remain limited. Many will have already
failed multiple traditional DMARDs prior to starting their first
anti-TNF therapy. Options include yet another trial of traditional
DMARDs, or even corticosteroids, continuing on their initial
anti-TNF therapy despite an inadequate response or switching to
a different biologic agent. Until recently, the choice of switching
to a second biologic agent has been limited to switching between
anti-TNF therapies and the availability of newer biologic agents
remains limited in many countries.
The evidence for switching between anti-TNF therapies in
patients who have had lack of response to their first anti-TNF
therapy is growing. Many small case series and open-label studies
have demonstrated good responses in patients switching for both
primary and secondary inefficacy, as well as adverse events [10].
However, the majority of these studies were very small and often
combined patients who have switched for inefficacy or adverse
events. The response to a second anti-TNF will differ based on the
reason for the switch [11, 12]. In addition, most studies to date
have not included a comparison with other treatment options and
have only focused on disease activity and not longer term
outcomes, such as disability. Therefore, the aim of this analysis
was to assess disability in a group of RA patients 12 months after
failing to respond to a first anti-TNF therapy, depending on sub-
sequent management over those 12 months.
Patients and methods
Patient selection
Patients for this study were selected from the large British Society
for Rheumatology Biologics Register (BSRBR). The details of this
study have been described elsewhere [13]. Briefly, as part of the
UK national guidelines, patients with RA starting anti-TNF
therapy are registered with the BSRBR, the purpose being to
systematically follow these patients for short- and long-term
outcomes including drug safety and efficacy. The register is still
actively recruiting and following new patients starting anti-TNF
therapy.
The UK national guidelines recommend that anti-TNF
therapies are administered to patients with active RA, defined
as a disease activity score in 28 joints (DAS28) >5.1 despite
previous therapy with at least two DMARDs, one of which
should be MTX. During the period of recruitment, etanercept
was administered as a subcutaneous injection either once (50mg)
or twice (25mg) weekly and adalimumab was administered as
a subcutaneous injection 40mg fortnightly. The suggested starting
dose of infliximab was 3mg/kg administered in conjunction
with MTX.
Baseline assessment
Baseline data, including demographics, diagnosis, disease dura-
tion, DAS28 [14], past and current anti-rheumatic therapies and
comorbidities are collected by the patient’s rheumatologist and/or
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separate questionnaire as well as the HAQ adapted for British
use [15].
Follow-up
Rheumatologists are sent a follow-up questionnaire every 6
months. Of relevance to this analysis, the rheumatologist records
whether their patient’s registered anti-TNF drug has been
continued, switched to another biologic drug or stopped. The
reasons for stopping or switching treatment are based on the
physician’s opinion, as recorded in the medical charts, and
classified into lack of efficacy, adverse events or other reasons.
Changes in non-biologic DMARDs are also captured. In addi-
tion, the most recent DAS28 is recorded at each 6-month
follow-up. This measurement may or may not correlate with
changes in therapy. Patients are contacted separately by post and
asked to complete a HAQ score on a 6-monthly basis.
Statistical analysis
This analysis was limited to patients with a physician’s diagnosis
of RA who were classified as non-responders to their first anti-
TNF agent within the first 12 months of therapy. Patients who
discontinued their first anti-TNF therapy for an adverse event
were excluded. Patients could be classified as non-responders in
two separate ways:
(i) Drug discontinuation: Patients who discontinued their first
anti-TNF therapy in the first 12 months of use with the
reason listed as ‘inefficacy’ were classified as non-responders,
regardless of changes in their DAS28 score. The date of
discontinuation, defined as the first missed dose, was taken
as the date of first non-response.
(ii) EULAR response: Using the DAS28 measured at baseline,
6 and 12 months, patients could also be classified as non-
responders based on the EULAR improvement criteria [16].
Response was first assessed in all patients after 6 months.
To account for possible secondary inefficacy, patients who
were responders at 6 months but non-responders at 12
months were also included. The date of non-response was
taken as the date of the first DAS28 score (i.e. 6- or
12-month follow-up date) which classified the patient as a
non-responder.
The primary outcome measure in the study was change in HAQ
score in the subsequent 12 months following classification as a
non-responder. Patients were only included in the analysis if they
had a HAQ score recorded within 90 days of the date on which
they were first classified as a non-responder and a subsequent
HAQ recorded two follow-ups (or 12 months) later.
Non-responders were divided into three separate groups based
on subsequent management over the following 12 months (Fig. 1):
(i) Group 1—‘Stoppers’: discontinued anti-TNF therapy within
the first 12 months and did not start a subsequent anti-TNF
agent or other biologic drug during the next 12 months.
(ii) Group 2—‘Stayers’: continued on their original anti-TNF
agent despite being classified as a non-responder and
remained on therapy until at least within 90 days of the
final HAQ measurement (i.e. for a minimum of further
9 months).
(iii) Group 3—‘Switchers’: stopped their first anti-TNF therapy
within the first 12 months of therapy for non-response but
started a second anti-TNF therapy during the subsequent
12 months. To capture the full experience of patients who
switched between anti-TNF therapies, Group 3 included all
patients who started a second anti-TNF at any time during
the next 12 months. As this group was quite varied, we also
identified a group of patients within Group 3 who switched
early (within 90 days of being classified as a non-responder)
and remained on the second anti-TNF therapy at least until
within 90 days of the second HAQ measurement (Group 4—
‘Early Switchers’) to ensure at least 6 months treatment with
the second anti-TNF therapy.
Baseline characteristics (at the start of the first anti-TNF
therapy) were compared among the groups using Pearson chi-
squared and Kruskal–Wallis tests. The primary outcome was
the mean change in HAQ score in the 12 months following
classification as a non-responder. This outcome was compared
between those patients who discontinued all biologic therapy
(Stoppers) and each of the other three treatment groups, using
multivariable linear regression models. The models were adjusted
for age, gender, disease duration, DAS28 score at the start of first
therapy, DAS28 score at first non-response and HAQ score at first
non-response, as it was felt that these factors may have influenced
which treatment group patients were allocated to and may also
have influenced any further change in HAQ during the follow-up
period. All analysis was performed in STATA Version 9.2
[College Station (TX), Stata Corporation] [17].
Ethical approval
The BSRBR received ethical approval from the United Kingdom
North West Multi-centre Research Ethics Committee (MREC 00-
8-53). Written informed consent was obtained from the partici-
pants according to the Declaration of Helsinki [18].
Results
As of July 2006, a total of 10 993 patients with RA were registered
with the BSRBR. Of these, 4458 (41%) started etanercept, 3956
(36%) infliximab and 2579 (23%) adalimumab as their first anti-
TNF drug. As of July 2006, 9026 (82%) had reached at least
6 months of follow-up, 7640 (69%) at least 1yr, 5885 (53%) at
least 18 months and 5002 (46%) at least 2yrs of follow-up. During
the first 12 months, 424 had stopped their first anti-TNF drug for
an adverse event and were not included in this analysis. During
this same period, 978 patients had stopped for inefficacy (726 with
an HAQ recorded within 90 days of stop date) and 1925 were
classified as EULAR non-responders based on change in DAS28
(1384 with a HAQ recorded within 90 days of DAS28 date).
As many patients who stopped for inefficacy were also classified
as non-responders using the EULAR response, a total of 1725
patients were classified as non-responders and had a HAQ score
recorded within 90 days of being classified as a non-responder
(Fig. 1). The majority of these non-responders (88%) were
classified as non-responders at 6 months and 12% were classified
at 12 months.
Of the 1725 non-responders, 1222 (71%) had completed a
further 12 months of follow-up. Of these, 1033 (85%) patients had
a HAQ score recorded at this later follow-up. Of these 1033 non-
responders, 148 (14%) received no further anti-TNF therapy
during the subsequent 12 months (Stoppers), 331 (32%) switched
to a second anti-TNF therapy (Switchers) and 389 (38%)
continued on their first anti-TNF therapy for at least a further
9 months (Stayers), giving a total of 868 patients for this analysis
(Table 1). The remaining patients continued on their first anti-
TNF therapy beyond the date of non-response but discontinued
within the next 9 months and were not included in this analysis, as
disability measures did not correlate with drug discontinuation.
Compared with patients who were either Stayers or Switchers,
Stoppers were slightly older (61 vs 58yrs, P¼0.01) when starting
their first anti-TNF therapy (Table 2). Stayers tended towards a
lower HAQ and DAS28at the start of their first anti-TNF therapy
(Tables 2 and 3). Overall, the mean change in HAQ score with the
first anti-TNF agent in this group of non-responders (measured
at the point of first designation as non-responder) was  0.08U
(S.D. 0.32), demonstrating a small improvement. However, when
comparing the improvements between the three groups, Stayers
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anti-TNF therapy compared with both Stoppers and Switchers
(Table 3).
During the subsequent 12 months, Stoppers experienced no
change in their mean HAQ score. The greatest mean improvement
in HAQ score in the 12 months after classification as non-
responders was observed among Switchers, with Stayers falling in
between. This trend remained after adjusting for differences in
age, gender, disease duration, HAQ score and DAS score (at start
of first anti-TNF therapy and at time of failure).
As these scores represent mean improvements among the
groups, the proportion of patients who achieved a minimum
clinically important difference (MCID) (defined as improvement
in HAQ score of at least 0.22U) [19] were also identified. Among
Stoppers, only 22% reached this MCID compared with 31% of
Stayers and 36% of Switchers (P<0.01 compared with Stoppers).
The best response (46%) was seen among patients who switched
anti-TNF therapy early (n¼147) following inefficacy and
remained on therapy for at least 6 months (Early Switchers),
which was significantly greater than Stayers (31%) (P<0.01).
To explore the possible effects of background DMARD
therapy, the proportion of patients receiving DMARDs with
their first anti-TNF drug and the proportion that had a change
to therapy during the subsequent 12 months were analysed.
Overall, 61% of patients were receiving a DMARD with their
first anti-TNF therapy, which did not differ significantly
among the groups (Table 2). The majority of these patients were
receiving MTX (49% of all patients, 80% of all DMARD
prescriptions). Only 13% of Stayers reported a change in
DMARD therapy over the subsequent 12 months (change in
dose or new DMARD) compared with 32% of Stoppers and 32%
of Switchers (P<0.05).
Discussion
Data from small open-label studies and clinical trials have shown
that patients who are not responding to a first anti-TNF drug
can gain significant improvements in disease activity when
switched to a second anti-TNF agent [10] and a recent clinical
trial has suggested that this improvement will exceed any further
improvement in disease activity which may be expected from
staying on the less effective drug [20]. Our data suggest that
patients who do not respond to a first anti-TNF drug may also
subsequently gain improvements in HAQ score, if switched to a
second agent.
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FIG. 1. Patient flow. FUP, follow-up.
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despite similar mechanisms of action, remains unexplained, but
possible hypotheses include differential bioavailability of these
drugs, differences in stability of the drug–TNF complex and the
development of anti-drug antibodies [21]. Differences in patient
adherence among these three agents may also play a role.
Unfortunately, the relatively small number of patients who
switched therapy in this analysis precluded any specific between-
drug comparisons.
Inherent to this analysis is the limitation of using observational
data to measure treatment response. Thus, while the analysis did
capture outcomes among patients as they occurred in the real
world, there is no doubt that there was still some selection of
patients as to whether they started any anti-TNF therapy in the
first instance, whether they stopped therapy if they were not
responding adequately, and later whether they switched to a
second agent. Decisions on treatment and thresholds for stopping
will have changed over the course of this study, due to availability
of different anti-TNF agents and physicians’ experience over time,
which may act to limit the external validity of these results. We
attempted to adjust for factors which may have influenced a
physician’s decision to start and stop therapy, including age,
disease duration, DAS28 and HAQ scores, and found that this
actually made little difference to the results. Further adjustment
used to model physicians’ decisions using inverse probability of
treatment weighting [22], which included DAS28 scores 6 months
after a patient was classified as a non-responder, were also
employed, but did not alter the results (data not shown).
Unfortunately, as discussed subsequently, missing DAS28 scores
excluded many patients from this model. There is also a strong
possibility that other unmeasured confounders, particularly
related to the patient, may have influenced these results.
Although all of these patients were classified as non-responders,
only half stopped therapy and only two-thirds of these switched to
a second agent. Factors such as past experience of DMARD
therapy, the occurrence of minor adverse events alongside the lack
of response and other psychological factors may have influenced
a patient’s decision to switch to a second anti-TNF agent. These
same factors may also have influenced the patients’ HAQ scores.
In addition, as during the main BSRBR study, HAQ scores were
not obtained at the time of treatment decisions but rather at
regular 6-month intervals, we had to exclude a proportion of
patients in order to only use those scores that did correlate with
changes to treatment or measures of disease activity. It is possible
that the outcomes of these excluded patients may have differed.
In this large cohort of anti-TNF-treated RA patients, over 50%
of patients remained on therapy despite a sub-optimal response.
Interestingly, this group of patients continued to gain further
improvements in HAQ score, despite fewer changes to back-
ground DMARD therapy. Why so many patients should remain
on a therapy without a significant improvement in DAS28
remains unclear. In the UK, practice guidelines suggest that
patients should discontinue therapy if an improvement in DAS28
of at least 1.2U is not achieved after 3 months (or after 6 months
if other improvements in disease had been observed at 3 months)
[23]. The treatment options in the UK at the time of this analysis
(as of July 2006) for patients who had failed anti-TNF therapy
were limited to stopping anti-TNF therapy and reverting to
traditional DMARDs and/or corticosteroids, continuing anti-
TNF therapy despite a lack of response or switching to a second
anti-TNF agent. Both rituximab and abatacept received a
European licence in 2007, a year following this analysis. Initial
UK guidelines [23] for the use of anti-TNF agents in RA did not
recommend switching between therapies, and therefore many
hospitals may have been unable to obtain funding for a second
course of anti-TNF therapy. As most of these patients had already
failed on average four DMARDs, there likely remained no other
alternative other than continue a less effective therapy. However,
we also observed that the best improvement in HAQ scores with
the first anti-TNF therapy were observed among patients who
subsequently remained on therapy, and therefore, it is possible
that despite a lack of significant improvement in DAS28, patients
may have felt better and therefore, their rheumatologist elected to
maintain this therapy despite a suboptimal response. It is also
likely that, due to reasons discussed earlier, patients may also have
been kept on their second anti-TNF drug despite a lack of
response, and therefore our measurement of response among
Switchers may also be an underestimate of the treatment effect.
The primary outcome measure chosen in this analysis was mean
change in HAQ score in the 12 months following non-response to
a first anti-TNF therapy. The HAQ was selected as it is a good
measure of longer-term outcomes in arthritis. However, in
patients with long-standing RA, HAQ scores may correlate
more with damage rather than with disease activity, and it has
been shown that HAQ scores are less responsive to treatment at
this later stage [24]. The median disease duration in this cohort
was 12yrs. However, despite this possible limitation, HAQ scores
TABLE 3. Mean changes in HAQ scores
Group
HAQ at start of
first anti-TNF therapy
mean (S.D.)
HAQ when classified
as non-responder
mean (S.D.)
Mean change in HAQ
score on first anti-TNF
therapy
a, Mean (S.D.)
HAQ measured
12 months after non-
response mean (S.D.)
Adjusted
b change in
HAQ over 12 months
Mean (95% CI)
Patients with at least 0.22U
improvement in HAQ over
subsequent 12 months
c n (%)
Stoppers (148) 2.21 (0.48) 2.19 (0.51)  0.03 (0.37) 2.19 (0.56) Referent 33 (22)
Stayers (389) 2.08 (0.54) 1.96 (0.60)  0.13 (0.20) 1.90 (0.59)  0.12 ( 0.23,  0.02) 123 (31)
All Switchers (331) 2.15 (0.48) 2.10 (0.52)  0.05 (0.31) 1.98 (0.60)  0.15 ( 0.26,  0.05) 120 (36)
Early Switchers (147) 2.10 (0.52) 2.03 (0.58)  0.07 (0.41) 1.90 (0.66)  0.18 ( 0.31,  0.06) 61 (42)
aUsing HAQ scores measured at start of first anti-TNF therapy and at time of first designation as non-responder.
bAdjusted for age, gender, disease duration, HAQ at first failure, DAS28at start of first
anti-TNF, DAS28at first failure.
cDifference in proportion between Stayers/Stoppers and Switchers/Stoppers (P¼0.01). Difference between All Switchers and Stayers (P¼0.19). Difference between
Early Switchers and Stayers (P¼0.03).
TABLE 2. Characteristics of patients at start of first anti-TNF therapy
Stoppers
(148)
Stayers
(389)
Switchers
(331)
Early
Switchers (147)
Age (yrs)
  61 (53, 68) 58 (49, 66) 58 (49, 65) 57 (49, 64)
Female, n (%) 120 (81) 314 (81) 263 (79) 116 (79)
Disease duration
(yrs)
12 (7, 19) 12 (6, 19) 11 (6, 19) 12 (6, 20)
DAS28
  6.6 (5.9, 7.3) 6.3 (5.6, 6.9) 6.7 (6.1, 7.5) 6.6 (6.0, 7.4)
Previous DMARDs 4 (3, 6) 4 (3, 5) 4 (3, 6) 4 (3, 6)
DMARD, n (%) 82 (55) 241 (62) 210 (63) 91 (62)
MTX, n (%) 73 (49) 200 (51) 156 (47) 70 (48)
Oral steroid
y, n (%) 89 (58) 187 (48) 157 (47) 63 (42)
NSAID, n (%) 84 (57) 247 (64) 220 (66) 105 (71)
 Difference observed between Stoppers, Stayers and Switchers, P<0.01.
yDifference
observed between Stoppers, Stayers and Switchers, P¼0.07. All results are given in median
(IQR) unless stated.
TABLE 1. Details of anti-TNF therapy
First anti-TNF
(n¼868)
Second anti-TNF
(n¼331)
Etanercept (%) 44 45
Infliximab (%) 37 17
Adalimumab (%) 19 38
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disease following effective disease control. During clinical trials
of anti-TNF therapies in biologically naive patients, the mean
improvement in HAQ score in the active treatment arms was in
the range of 0.5 U over 6–12 months [1–3]. However, it may not be
realistic to expect such an improvement among a group of patients
who have already failed one anti-TNF agent. Patients are also
more likely to stop a second anti-TNF agent for inefficacy if they
had also stopped their first agent for inefficacy [25]. Thus, while
the degree of response among individual patients who do respond
to a second anti-TNF drug may be equivalent to that seen with a
first agent, the proportion of patients who do respond will be
lower and thus, the mean improvement among a group of patients
will also be lower.
DAS28 was not selected as the primary outcome measure
for two main reasons. First, it was felt that, in this uncontrolled
study, where other non-biologic therapies are allowed, changes in
DAS28 over 12 months may not necessarily reflect only changes to
anti-TNF therapies. Short-term interventions, such as cortico-
steroid injections, are as likely to reduce swollen and tender joint
counts and ESR. Whilst we have shown that DMARD use did
not vary significantly between the groups in the subsequent
12 months’ of follow-up, unfortunately, we did not record details
of joint injections or details of intra-muscular injections, which
may also have had an influence upon DAS28 scores. In addition,
we found that over time, patients were less likely to have a DAS28
recorded, particularly if anti-TNF therapy was discontinued or
if there had been no changes to therapy for a prolonged period
of time.
In conclusion, patients with long-standing disease who do not
respond to their first anti-TNF therapy discontinue this first drug
and receive no biologic therapy in the subsequent 12 months do
not experience any further mean improvements in HAQ score
over this 12-month period. Patients who continue on their first
anti-TNF drug despite a suboptimal improvement in DAS28 gain
some further improvement in HAQ score, suggesting that
biologics may continue to provide additional benefit to patients
beyond the first few months of treatment. However, the best
response was seen among patients who switched to a second anti-
TNF therapy.
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